Nationwide utilization of antidepressants and anxiolytics during pandemic restrictions: results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study
Family Practice · 14.08.2025 · 42 (5)
DOI: 10.1093/fampra/cmaf072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Family Practice, online erschienen am 26.08.2025. Verfasst von Caner Vizdiklar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul 34854, Turkey. Hauptthemen laut MEDLINE: Anti-Anxiety Agents, Antidepressive Agents, COVID-19, Drug Utilization. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Health Institutes of Turkey.
Abstract (Originalsprache)
Background
The prevalence of mental health disorders rose when the impact of the COVID-19 pandemic was most pronounced, potentially altering the consumption of antidepressants and anxiolytics. We aimed to evaluate changes in antidepressant and anxiolytic utilization throughout the COVID-19 pandemic era.
Methods
Nationwide drug sales and prescribing data through 01.03.2018–31.12.2022 were sourced from IQVIA Turkey. We assessed mean monthly consumption and expenditure trends of antidepressants and anxiolytics, along with quarterly prescribing levels, across three periods: “before restrictions” (BfR, 01.03.2018–31.03.2020), “during restrictions” (DuR, 01.04.2020–31.03.2022), and “after restrictions” (AfR, 01.04.2022–31.12.2022), using “defined daily dose per 1000 inhabitants per day” (DID) measure.
Results
Antidepressant consumption escalated from 47.9 ± 4.3 DID in BfR to 56.2 ± 8.9 DID in DuR (P < .001), reaching 60.5 ± 8.9 DID in AfR (P < .001 vs. BfR). Anxiolytic use increased from 2.0 ± 0.3 DID in BfR to 2.5 ± 0.3 DID in DuR (P < .001), and to 2.7 ± 0.3 DID in AfR (P < .001 vs. BfR). Expenditure also rose in DuR and AfR for both drug groups (P < .01). Prescribing trends for antidepressants decreased in DuR (P < .001) and showed an insignificant rebound in AfR (P > .05 vs. BfR and DuR), while anxiolytic prescribing surged in DuR (P = .001 vs. BfR) and subsequently reverted in AfR (P > .05 vs. BfR and DuR). These patterns were consistent across both new and ongoing users.
Conclusions
This study showed a sustained increase in the use of antidepressants and anxiolytics following the onset of pandemic despite fluctuations in prescribing, implying a heightened need for pharmacotherapy and greater burden of depressive and anxiety disorders, especially for the latter.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul 34854, Turkey.
- Department of Clinical Trials, Turkish Medicines and Medical Devices Agency, Ankara 06520, Turkey.
- Department of Basic Medical Sciences/Pharmacology, Marmara University School of Dentistry, Istanbul 34854, Turkey.
- Marmara University Institute of Health Sciences, Istanbul 34865, Turkey.
- Department of Psychiatry, Antalya Training and Research Hospital, Antalya 07100, Turkey.
ORCID-Profile: Caner Vizdiklar, Volkan Aydin, Hakan Yilmaz, Ahmet Akici
Förderung
- Health Institutes of Turkey
Zitieren
APA
Vizdiklar, C., Aydin, V., Yilmaz, H., & Akici, A. (2025). Nationwide utilization of antidepressants and anxiolytics during pandemic restrictions: results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study. Family Practice, 42(5). https://doi.org/10.1093/fampra/cmaf072
Vancouver
Vizdiklar C, Aydin V, Yilmaz H, Akici A. Nationwide utilization of antidepressants and anxiolytics during pandemic restrictions: results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study. Family Practice. 2025;42(5). doi:10.1093/fampra/cmaf072
BibTeX
@article{Vizdiklar2025,
author = {Vizdiklar, Caner and Aydin, Volkan and Yilmaz, Hakan and Akici, Ahmet},
title = {Nationwide utilization of antidepressants and anxiolytics during pandemic restrictions: results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study},
journal = {Family Practice},
year = {2025},
volume = {42},
number = {5},
doi = {10.1093/fampra/cmaf072}
}
EUVIMED